SARS-CoV-2 mRNA vaccine (delta variant) (Pfizer/BioNTech)

N/A

Report date: 2025/12/12 17:32:41

Base Information

Drug NameSARS-CoV-2 mRNA vaccine (delta variant) (Pfizer/BioNTech)
Drug Alias NameCOVID-19 mRNA vaccine (Pfizer/BioNTech)
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncBiontech Se
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A